Tezosentan Uses, Dosage, Side Effects and more
Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.
| Trade Name | Tezosentan |
| Generic | Tezosentan |
| Tezosentan Other Names | Tezosentan |
| Type | |
| Formula | C27H27N9O6S |
| Weight | Average: 605.625 Monoisotopic: 605.180500331 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in congestive heart failure, liver disease, and heart disease.
Half Life
A pronounced and rapid disposition phase (half-life 6 min), accounting for the major part of the elimination, was followed by a slower phase (half-life 3 h), probably caused by distribution from tissues.
